Molecule Details
| InChIKey | JLCCNYVTIWRPIZ-NRFANRHFSA-N |
|---|---|
| Canonical SMILES | CC(=O)N1CCC(Nc2cc(C(=O)NC[C@H](O)CN3CCc4ccccc4C3)ncn2)CC1 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 2 |
| Pfam Stratification | Cross-Family |
| Avg pChEMBL | 8.12 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB19170 |
|---|---|
| Drug Name | Pemrametostat |
| CAS Number | 1616392-22-3 |
| Groups | investigational |
| ATC Codes | nan |
| Description | Pemrametostat is under investigation in clinical trial NCT03614728 (Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)). |
Categories: Enzyme Inhibitors Heterocyclic Compounds, Fused-Ring
Cross-references: BindingDB: 178166 CHEMBL4466233 ChemSpider: 58178564 PDB: A1BLM ZINC: ZINC000220119494
Target Activities (2)
DrugBank Target Actions (1)
| Target | Gene | Target Name | Action | Type |
|---|---|---|---|---|
| O14744 | PRMT5 | Protein arginine N-methyltransferase 5 | inhibitor | targets |